These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 8686503

  • 1. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
    Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF.
    J Bone Miner Res; 1995 Oct; 10(10):1478-87. PubMed ID: 8686503
    [Abstract] [Full Text] [Related]

  • 2. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 3. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O, Tiedemann K, Komarova SV.
    Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
    [Abstract] [Full Text] [Related]

  • 4. Antitumor effects of bisphosphonates.
    Green JR.
    Cancer; 2003 Feb 01; 97(3 Suppl):840-7. PubMed ID: 12548584
    [Abstract] [Full Text] [Related]

  • 5. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
    Kellinsalmi M, Mönkkönen H, Mönkkönen J, Leskelä HV, Parikka V, Hämäläinen M, Lehenkari P.
    Basic Clin Pharmacol Toxicol; 2005 Dec 01; 97(6):382-91. PubMed ID: 16364054
    [Abstract] [Full Text] [Related]

  • 6. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 01; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

  • 7. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI, Rojas J, Greig IR, Van't Hof RJ, Ralston SH.
    Calcif Tissue Int; 2008 Mar 01; 82(3):191-201. PubMed ID: 18259679
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.
    Hughes DE, MacDonald BR, Russell RG, Gowen M.
    J Clin Invest; 1989 Jun 01; 83(6):1930-5. PubMed ID: 2524504
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
    Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM.
    Calcif Tissue Int; 2004 Jul 01; 75(1):71-7. PubMed ID: 15037971
    [Abstract] [Full Text] [Related]

  • 10. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P, Nguyen H, Barbier A, Baron R.
    J Bone Miner Res; 1996 Oct 01; 11(10):1498-507. PubMed ID: 8889850
    [Abstract] [Full Text] [Related]

  • 11. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
    Sato M, Grasser W.
    J Bone Miner Res; 1990 Jan 01; 5(1):31-40. PubMed ID: 2106763
    [Abstract] [Full Text] [Related]

  • 12. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
    Fournier PG, Daubiné F, Lundy MW, Rogers MJ, Ebetino FH, Clézardin P.
    Cancer Res; 2008 Nov 01; 68(21):8945-53. PubMed ID: 18974139
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 14. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
    D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG, Bernabei P, Cristofaro MA, Pescarmona GP, Isaia G.
    J Bone Miner Res; 2008 Mar 15; 23(3):373-9. PubMed ID: 17967134
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K.
    Adv Drug Deliv Rev; 2005 May 25; 57(7):959-71. PubMed ID: 15876398
    [Abstract] [Full Text] [Related]

  • 16. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M.
    Bone; 2004 Nov 25; 35(5):1144-56. PubMed ID: 15542040
    [Abstract] [Full Text] [Related]

  • 17. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 25; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 18. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R, Croucher PI.
    Cancer Res; 2007 Jan 01; 67(1):202-8. PubMed ID: 17210700
    [Abstract] [Full Text] [Related]

  • 19. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
    Zhang Q, Badell IR, Schwarz EM, Boulukos KE, Yao Z, Boyce BF, Xing L.
    Arthritis Rheum; 2005 Sep 01; 52(9):2708-18. PubMed ID: 16142752
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of action of the bisphosphonates.
    Fleisch H.
    Medicina (B Aires); 1997 Sep 01; 57 Suppl 1():65-75. PubMed ID: 9567358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.